Chronic Lung Allograft Dysfunction (CLAD) Clinical Trial
| Verified date | February 2017 |
| Source | Fraunhofer-Institute of Toxicology and Experimental Medicine |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
It's the aim of this study to clarify, whether the non-invasive assessment of breath can serve as a novel clinical tool to assist in the diagnosis of CLAD. If different stages of BOS can be discriminated by the level of certain VOCs than there would also be a potential to actually predict the development at an early stage and would enable an earlier intervention.
| Status | Completed |
| Enrollment | 75 |
| Est. completion date | December 2016 |
| Est. primary completion date | December 2016 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 80 Years |
| Eligibility |
Inclusion Criteria: - Outpatient bilateral lung transplant recipients including combined transplants Exclusion Criteria: - Active Smoking Oxygen therapy Infection with multi or pan-resistant bacteria |
| Country | Name | City | State |
|---|---|---|---|
| Germany | Hannover Medical School | Hannover |
| Lead Sponsor | Collaborator |
|---|---|
| Prof. Dr. Jens Hohlfeld | Hannover Medical School |
Germany,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Concentration of exhaled breath volatile organic compounds | one sample will be collected between 6 month and 20 years after lung transplantation |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02709343 -
Trial of Bone-marrow Derived Mesenchymal Stromal Cells (MSC) for New Onset Chronic Lung Allograft Dysfunction
|
Phase 2 |